Acute myeloid leukemia is a rapidly advancing blood cancer that requires swift and carefully planned treatment. The journey involves intensive chemotherapy, supportive care, and in many cases, a stem cell transplant—all designed to push the disease into remission and offer the best chance for a longer, healthier life.

Treatment Goals and the Path Ahead

When someone receives a diagnosis of acute myeloid leukemia, often shortened to AML, the focus immediately turns to treatment. This is not a condition where waiting is an option, because AML grows quickly and aggressively. The main goals of treating this disease are to eliminate as many cancer cells as possible from the blood and bone marrow, to control troubling symptoms like fatigue and infections, to restore normal blood cell production, and to improve how patients feel day to day. Treatment is also about reducing the risk of the disease coming back, which doctors call a relapse.^[6][10]

The treatment plan for AML is not the same for everyone. Doctors consider many factors before deciding on the best approach. These include the patient’s age, overall health, the specific subtype of AML they have, and whether certain genetic changes or chromosome abnormalities are present in the leukemia cells. Younger, fitter patients may be able to tolerate more intensive chemotherapy, while older adults or those with other medical problems might need gentler treatment options. The disease itself also plays a role—some subtypes respond better to certain drugs than others.^[3][12]

There are established, standard treatments for AML that have been refined over decades and are recommended by medical guidelines. At the same time, researchers are constantly exploring new therapies in clinical trials. These experimental treatments may involve newer drugs, targeted therapies that attack specific mutations in cancer cells, or innovative approaches like gene therapy and immunotherapy. Joining a clinical trial can sometimes give patients access to promising treatments that are not yet widely available.^[6][13]

Standard Treatment: Chemotherapy and Beyond

Chemotherapy forms the backbone of AML treatment. This powerful medicine works by killing rapidly dividing cells, including the abnormal white blood cells that characterize leukemia. The treatment is typically divided into phases, each with a specific purpose.^[6][12]

The first phase is called induction therapy. The goal here is to achieve what doctors call a complete remission, meaning that leukemia cells are no longer detectable in the blood or bone marrow, and normal blood cell counts are restored. Induction usually involves a combination of two or more chemotherapy drugs given through a vein over several days. Common drug combinations include cytarabine and an anthracycline drug like daunorubicin or idarubicin. This phase is intense. Patients typically stay in the hospital because their immune system becomes very weak, making them vulnerable to infections. They often need blood transfusions to replace red blood cells and platelets that the chemotherapy and the leukemia itself have destroyed.^[12][16]

Once remission is achieved, the next step is consolidation therapy, also known as post-remission therapy. The purpose of consolidation is to kill any remaining leukemia cells that might be hiding in the body, even though they cannot be detected by standard tests. Without this step, the disease is very likely to return. Consolidation often involves more chemotherapy, sometimes at higher doses, or it may include a stem cell transplant. This phase can last several months.^[12][16]

Some patients, particularly those who are not going to have a transplant and who have certain higher-risk genetic features, may also receive maintenance therapy. This is a longer phase of treatment with lower-dose chemotherapy, designed to keep the disease away for as long as possible.^[16]

A stem cell transplant, also called a bone marrow transplant, is currently the only treatment that can potentially cure AML. It involves destroying the patient’s diseased bone marrow with very high doses of chemotherapy and sometimes radiation, then replacing it with healthy stem cells from a donor or, less commonly, from the patient’s own body. This is a major procedure with significant risks, including serious infections and a condition called graft-versus-host disease, where the donor cells attack the patient’s tissues. Not everyone is a candidate for a transplant, but for those who are, it can offer the best chance of long-term survival.^[3][12]

For patients who cannot tolerate intensive chemotherapy—often older adults or those with other health problems—doctors may recommend less aggressive treatment. This might involve lower doses of chemotherapy, often given as pills or injections, that can sometimes be administered on an outpatient basis. The goal is still to control the disease and improve quality of life, even if the treatment is not as strong.^[12]

Special Treatment for Acute Promyelocytic Leukemia

One subtype of AML, called acute promyelocytic leukemia or APL, is treated differently from other forms. This is because APL has a specific genetic change involving chromosomes 15 and 17. Patients with APL receive a drug called all-trans retinoic acid, or ATRA, along with chemotherapy. ATRA works by helping the immature white blood cells mature into normal, functioning cells. Another drug, arsenic trioxide, is also highly effective in APL and can be used alone or with ATRA. This combination has transformed APL from one of the deadliest forms of leukemia into one of the most curable.^[12][13]

Innovative Treatments Being Tested in Clinical Trials

While standard chemotherapy and transplants remain the mainstay of AML treatment, researchers are developing a new generation of therapies that are more precise and potentially less toxic. Many of these are being tested in clinical trials, which are carefully designed research studies that evaluate whether new treatments are safe and effective.^[6][13]

Targeted therapies are drugs that attack specific genetic mutations or abnormalities found in leukemia cells. Unlike traditional chemotherapy, which kills all rapidly dividing cells, targeted therapies are designed to affect only cells with a particular molecular feature. This can make them more effective and cause fewer side effects.^[18]

One example is drugs that target mutations in the FLT3 gene, which are present in about one-third of AML cases. Drugs like midostaurin, gilteritinib, and quizartinib block the abnormal protein produced by this mutation, slowing or stopping the growth of leukemia cells. These drugs are used in combination with chemotherapy or on their own in patients whose disease has come back after initial treatment. Clinical trials have shown that adding FLT3 inhibitors to chemotherapy can improve survival in patients with this mutation.^[18]

Another target is the IDH1 or IDH2 gene mutations, found in about 20 percent of AML patients. Drugs like ivosidenib (for IDH1 mutations) and enasidenib (for IDH2 mutations) work by correcting the abnormal metabolism in leukemia cells, allowing them to mature normally or die. These are taken as pills and are generally well tolerated. Early trial results have shown that these drugs can lead to remission in some patients whose leukemia has relapsed or who are not candidates for intensive chemotherapy.^[18]

BCL-2 inhibitors are another class of targeted drugs. The BCL-2 protein helps cancer cells survive by preventing them from dying. Venetoclax is a drug that blocks BCL-2, triggering cancer cell death. It is often combined with other low-intensity chemotherapy drugs like azacitidine or decitabine, particularly in older patients or those who cannot tolerate intensive chemotherapy. Clinical trials have demonstrated that this combination can produce high remission rates with manageable side effects.^[18]

Immunotherapy is a relatively new approach that harnesses the power of the patient’s own immune system to fight cancer. One type of immunotherapy being studied in AML is monoclonal antibodies, which are laboratory-made proteins that can recognize and attach to specific targets on leukemia cells, marking them for destruction by the immune system. Another approach involves CAR T-cell therapy, where a patient’s own immune cells are collected, genetically modified to recognize leukemia cells, and then infused back into the patient. While CAR T-cell therapy has had dramatic success in some other types of leukemia, it is still in early-stage trials for AML.^[18]

Some clinical trials are exploring bispecific antibodies, which can simultaneously bind to a target on a leukemia cell and to an immune cell, bringing them together so the immune cell can attack the cancer. These are being tested in Phase I and Phase II trials to assess safety and effectiveness.^[18]

Clinical trials are typically divided into phases. Phase I trials test a new drug or treatment for the first time in a small group of people to evaluate its safety, determine a safe dosage range, and identify side effects. Phase II trials involve more participants and aim to assess whether the treatment works for a specific condition and to further evaluate safety. Phase III trials compare the new treatment to the current standard treatment to see which is better. These trials involve large groups of patients and are often conducted in multiple locations, including hospitals in Europe, the United States, and other regions.^[6][13]

Patients interested in joining a clinical trial should discuss this option with their healthcare team. Trials often have specific eligibility criteria, such as age, type of AML, previous treatments received, and overall health status. Participating in a trial can provide access to cutting-edge treatments, but it also involves uncertainty, as not all experimental therapies prove to be effective.^[6][18]

Most common treatment methods

• Intensive chemotherapy
  • Combination of cytarabine and anthracycline drugs such as daunorubicin or idarubicin administered intravenously during induction phase
  • High-dose chemotherapy in consolidation phase to eliminate remaining leukemia cells
  • Requires hospital stay due to severe immune suppression and need for blood transfusions
  • Common side effects include nausea, vomiting, hair loss, mouth sores, diarrhea, and high infection risk
• Non-intensive chemotherapy
  • Lower-dose chemotherapy suitable for older patients or those unable to tolerate intensive treatment
  • Often given as pills, injections, or outpatient infusions
  • May be combined with targeted drugs like venetoclax for improved effectiveness
  • Fewer side effects but may not achieve as deep or durable remissions
• Stem cell (bone marrow) transplant
  • The only potentially curative treatment for AML
  • Involves high-dose chemotherapy and/or radiation to destroy diseased bone marrow, followed by infusion of healthy donor or patient’s own stem cells
  • Major risks include serious infections, graft-versus-host disease, and transplant-related complications
  • Not suitable for all patients; depends on age, health status, and availability of a matched donor
• Targeted therapy
  • FLT3 inhibitors such as midostaurin, gilteritinib, and quizartinib for patients with FLT3 gene mutations
  • IDH inhibitors like ivosidenib and enasidenib for patients with IDH1 or IDH2 mutations
  • BCL-2 inhibitor venetoclax, often combined with azacitidine or decitabine
  • Drugs target specific genetic abnormalities in leukemia cells, potentially offering better results with fewer side effects than traditional chemotherapy
• Treatment for acute promyelocytic leukemia (APL)
  • All-trans retinoic acid (ATRA) helps immature white blood cells mature into normal cells
  • Arsenic trioxide speeds up death of leukemia cells and promotes normal cell development
  • Used in combination with or instead of traditional chemotherapy
  • Has transformed APL from one of the deadliest to one of the most curable forms of AML
• Radiotherapy
  • High-dose controlled radiation used to kill leukemia cells
  • Often used to prepare the body for a stem cell transplant
  • May be used to treat disease that has spread to the brain or spinal cord, though this is uncommon
  • Side effects can include fatigue, hair loss, nausea, and skin changes in the treated area
• Immunotherapy (experimental in clinical trials)
  • Monoclonal antibodies that attach to leukemia cells and mark them for immune system destruction
  • CAR T-cell therapy, where patient’s immune cells are genetically modified to recognize and attack leukemia cells
  • Bispecific antibodies that bring immune cells and leukemia cells together
  • Still in early-stage clinical trials for AML; showing promise in some patients

Managing Side Effects and Supporting the Body During Treatment

AML treatment is demanding, and side effects are common. Understanding what to expect and how to manage these effects can help patients feel more in control and improve their quality of life during treatment.^[12][15]

Because chemotherapy kills both cancer cells and healthy cells that divide quickly—such as those in the bone marrow, digestive tract, and hair follicles—patients may experience a range of side effects. These include nausea and vomiting, which can often be controlled with anti-nausea medications. Diarrhea and mouth sores are also common and may require dietary adjustments and special mouth rinses. Hair loss is expected with many chemotherapy regimens, although hair typically grows back after treatment ends.^[12][15]

One of the most serious risks during AML treatment is infection. Chemotherapy severely lowers the number of white blood cells, particularly neutrophils, which are crucial for fighting infections. Patients may need to stay in the hospital in a clean, controlled environment during the most vulnerable phases of treatment. Antibiotics, antifungal drugs, and antiviral medications are often given preventively. Patients are advised to avoid crowded places, practice careful hand hygiene, and avoid raw or undercooked foods that might carry bacteria.^[12][15]

Fatigue is another common and often overwhelming side effect. It can result from the disease itself, the treatment, or from anemia caused by low red blood cell counts. Blood transfusions can help with anemia, and patients are encouraged to rest when needed but also to stay as active as possible, even with light exercise like short walks.^[15][22]

Nutrition plays an important role in recovery and managing side effects. A diet rich in protein, complex carbohydrates, and healthy fats can help maintain strength and support the immune system. However, appetite loss, changes in taste, and difficulty swallowing can make eating challenging. Small, frequent meals and nutrient-dense foods like smoothies, soups, and nut butters can help. A dietitian can provide personalized guidance to meet individual needs.^[22][24]

Emotional and psychological support is equally important. Living with AML and undergoing intensive treatment can be frightening, isolating, and exhausting. Anxiety, depression, and feelings of uncertainty are common. Patients benefit from talking to counselors, joining support groups, and staying connected with family and friends. Palliative care services, which focus on symptom management and quality of life, can be integrated into treatment from the beginning and are not just for end-of-life care.^[22][23]

Follow-Up Care and Living After Treatment

After completing intensive treatment for AML, patients enter a phase of regular follow-up care. This is crucial for monitoring the disease and catching any signs of relapse as early as possible. Follow-up typically involves frequent blood tests to check blood cell counts and bone marrow biopsies to ensure no leukemia cells have returned. In the first months after treatment, appointments may be weekly or even more frequent, gradually spacing out to monthly and then every few months as time goes on.^[21]

Long-term side effects from treatment can include fatigue, heart problems from certain chemotherapy drugs, and infertility. Patients who have undergone a stem cell transplant may face additional challenges, including chronic graft-versus-host disease, which requires ongoing management. Doctors will monitor for these issues and provide supportive treatments as needed.^[12][21]

Adjusting to life after AML treatment is a process. Many patients describe feeling uncertain about the future and worried about the disease returning. Unlike some cancers that go away completely after treatment, AML can require long-term monitoring and, in some cases, ongoing low-dose therapy. This can make it hard to feel like life has returned to normal. Support from healthcare teams, counselors, and other patients who have been through similar experiences can be invaluable during this time.^[19][21]

Gradually increasing physical activity, maintaining a balanced diet, and staying engaged with hobbies and social connections can all help rebuild strength and improve quality of life. Some patients find it helpful to set small, achievable goals and celebrate progress along the way.^[22][24]